GSK Expands Share Buyback Program with Latest Purchase

GlaxoSmithKline ( (GB:GSK) ) has provided an announcement.

GSK has announced the purchase of 170,000 of its own ordinary shares as part of its ongoing buyback program, with shares acquired through BNP Paribas SA. The shares will be held as treasury shares, and this transaction contributes to the company’s strategy to manage its capital structure and return value to shareholders. The buyback program, initiated on 30 September 2025, has seen GSK purchase a total of 10,478,000 shares. This move is expected to impact the company’s voting rights and shareholding structure, with 5.78% of voting rights now attributable to treasury shares.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £2000.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.

GlaxoSmithKline’s strong technical indicators and positive earnings call sentiment are the most significant factors driving the high score. The company’s solid financial performance, despite some concerns about cash flow and debt reliance, supports a favorable outlook. Valuation metrics further enhance its attractiveness, making GSK a compelling investment in the drug manufacturing sector.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GlaxoSmithKline (GSK) is a global healthcare company that operates in the pharmaceutical industry, focusing on the development and production of vaccines, medicines, and consumer healthcare products.

Average Trading Volume: 8,761,735

Technical Sentiment Signal: Buy

Current Market Cap: £72.45B

For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.